Moderna plans a $2B convertible note offering; AstraZeneca-Amgen's Tezspire and Biokin's ADC post Phase 3 wins; Takeda exits China gene therapy deal; Gates Foundation backs ProFound on preeclampsia.
Plus news about Takeda China and ProFound.
Moderna’s $2B offering: The mRNA biotech will offer convertible senior notes for the “flexibility …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna Borrows $2 Billion To Expand Oncology Business - Moderna (NASDAQ:MRNA)
Moderna raises $2 billion in convertible notes for cancer vaccine
What’s in Merck and Moderna’s cancer vaccine algorithm?
Moderna Stock Slides Monday Following Historic Rally: What's Going On? - Moderna (NASDAQ:MRNA)
Moderna Stock Falls Friday: What's Going On? Moderna Stock Falls Friday: What's Going On? - Moderna (NASD
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study…
Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage…
The biotech company will sell notes due 2032, with an option to raise an additional $300 million, days after its stock hit a…
Moderna shares surged after positive Phase 3 results for its Merck-partnered melanoma cancer vaccine, boosting confidence in its…
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance…
Moderna still bullish on mRNA, Ipsen's acquisition of Kartos, and more biotech news from The Readout
